LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial

Core Viewpoint - LIXTE Biotechnology Holdings, Inc. is expanding its clinical trial for LB-100, a compound aimed at treating ovarian clear cell cancer, in collaboration with MD Anderson Cancer Center and GSK, with initial findings expected in 2026 [2][4]. Group 1: Clinical Trial Expansion - The ongoing clinical trial, initiated in January 2024, combines LB-100 with GSK's Dostarlimab to enhance immunotherapy effectiveness [3]. - The trial will double patient enrollment from 21 to 42 patients, with the initial target successfully met earlier this year [4]. - Data from the initial 21 patients is expected to be presented in the first half of 2026 [4]. Group 2: Company Insights - LIXTE is focused on developing innovative cancer therapies, with LB-100 being a first-in-class PP2A inhibitor that has shown potential in enhancing chemotherapy and immunotherapy [6][7]. - The company emphasizes the significant unmet need in treating ovarian clear cell cancer and aims to improve patient outcomes through its research [5]. - LIXTE's approach is part of a new field in cancer biology known as activation lethality, supported by a comprehensive patent portfolio [7].